Biodexa Pharmaceuticals (DB:5MP1) - Hisse Senedi Fiyatı, Haberler ve Analizler

5MP1 Stoklara Genel Bakış

5MP1 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 19.2% oranında arttı

Risk Analizi

Anlamlı bir piyasa değeri yok ( €3M )

Geliri 1 milyon ABD dolarından az ( £83K )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Biodexa Pharmaceuticals Plc Rakipler

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€24.9m

Epigenomics

DB:ECX

€980.2k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Biodexa Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$5.65
52 Haftanın En Yüksek Seviyesi	US$156.25
52 Haftanın En Düşük Seviyesi	US$5.45
Beta	1.44
11 Aylık Değişim	0%
3 Aylık Değişim	-56.54%
1 Yıllık Değişim	-90.26%
33 Yıllık Değişim	-99.99%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	5MP1	DE Biotechs	DE Pazar
7D	0%	-1.9%	-0.6%
1Y	-90.3%	-18.1%	9.6%

Getiri vs. Endüstri: 5MP1 geçen yıl % -18.1 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 5MP1 geçen yıl % 9.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 5MP1's price volatile compared to industry and market?
5MP1 volatility
5MP1 Average Weekly Movement	16.0%
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 5MP1 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 5MP1 'nin haftalık oynaklığı son bir yılda 35% dan 16% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	21	Stephen Stamp	www.biodexapharma.com

Klinik aşamada bir biyofarmasötik şirketi olan Biodexa Pharmaceuticals Plc, Tip 1 diyabet ve beynin nadir / yetim kanserlerinin tedavisi için bir ürün hattı geliştirmeye odaklanmaktadır. Lyn kinaz enziminin seçici bir aktivatörü olan öncü ürün adayı Tolimidone, şu anda Tip 1 diyabet tedavisi için Faz II çalışmaları altındadır. Şirket ayrıca şu anda yaygın intrinsik tekrarlayan glioblastoma, yaygın orta hat glioma ve medulloblastoma tedavisi için Faz I çalışmalarında olan MTX110'u ve leptomeningeal hastalığın tedavisi için şu anda klinik öncesi çalışmalarda olan, aynı anda veya sırayla doğrudan kanser mikroçevresine kolayca infüze edilebilen veya enjekte edilebilen suda çözünür bir ilaç formülasyonu etrafında odaklanan bir program olan MTD217'yi geliştirmektedir.

Biodexa Pharmaceuticals Plc Temel Bilgiler Özeti

Biodexa Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
5MP1 temel i̇stati̇sti̇kler
Piyasa değeri	€2.67m
Kazançlar(TTM)	-€8.18m
Gelir(TTM)	€99.57k

26.8x

P/S Oranı

-0.3x

F/K Oranı

5MP1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
5MP1 gelir tablosu (TTM)
Gelir	UK£83.00k
Gelir Maliyeti	-UK£62.00k
Brüt Kâr	UK£145.00k
Diğer Giderler	UK£6.96m
Kazançlar	-UK£6.82m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-11.74
Brüt Marj	174.70%
Net Kâr Marjı	-8,215.66%
Borç/Özkaynak Oranı	0%

5MP1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

5MP1 Stoklara Genel Bakış

Ödüller

Risk Analizi

Biodexa Pharmaceuticals Plc Rakipler

BST:BPXA

€772.4k

XTRA:CNW

€6.5m

XTRA:MDG1

€24.9m

DB:ECX

€980.2k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023)

Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Recent updates

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023)

Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009969 million.

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009968 million.

Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data

Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ At 12 Months in Familial Adenomatous Polyposis (Fap)

Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis

Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: UK£8.00 loss per share (vs UK£620 loss in FY 2022)

New minor risk - Financial data availability

Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

New major risk - Financial position

Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million.

New major risk - Financial position

Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano)

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs)

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015

Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule

Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements

Biodexa Pharmaceuticals Plc announced that it has received $3.320388 million in funding

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Biodexa Pharmaceuticals Plc (NasdaqCM:BDRX) entered into non-binding letter of intent to acquire Varian Biopharmaceuticals Inc. for $3.7 million.

Full year 2022 earnings released: UK£0.077 loss per share (vs UK£1.36 loss in FY 2021)

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Biodexa Pharmaceuticals Plc Temel Bilgiler Özeti